ASH 2021 | CPX-351 vs. HMA plus venetoclax in the treatment of patients with AML
In this video, Pinkal Desai, MD, MPH, Weill Cornell Medical College, New York, NY, shares some results from a multi-center retrospective analysis, which aimed to compare two frontline treatment regimens used for patients with acute myeloid leukemia (AML) – liposomal daunorubicin/cytarabine (CPX-351) versus hypomethylating agent (HMA) plus venetoclax (ven). Looking at data from four large U.S. medical academic centers, Dr Desai explains some of the interesting results observed, including whether there was a difference in complete remission rates or overall survival, as well as the benefits seen in TP53-mutated patients who received CPX-351. Dr Desai then discusses how higher rates of transplant in the CPX-351 group may account for some results, and that looking at more comorbidity data can help develop this area of research. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
